Wall Street kicked off the week with a fresh batch of Buy upgrades that cut across gold miners, biotech, wireless, regional banks, and identity software. Chair Kevin Warsh's June 17 FOMC held policy at 3.50%–3.75% and CME FedWatch still assigns roughly an 80% probability to zero cuts this year, so single-name catalysts continue to do most of the work. All five names below picked up formal Buy upgrades from bulge-bracket or specialist firms on July 6.
Agnico Eagle Mines (AEM) — Jefferies calls the pullback an entry point
Agnico Eagle is a senior gold producer with core operations in Canada, Finland, Mexico, and Australia. On July 6, Jefferies analyst Fahad Tariq upgraded the stock from Hold to Buy and raised his target from $187 to $200, citing recent share price weakness as an attractive entry point for a senior producer that offers "one of the sector's strongest combinations of asset quality, jurisdictional exposure, operational consistency, balance sheet strength, and visible production growth after 2029." Barclays's Richard Garchitorena reiterated Overweight at $210 the same day, CIBC's Anita Soni holds Outperformer $310, and UBS's Daniel Major sits at Neutral $170.
Shares traded at $154.84 on July 6, up 0.63%, with a market cap of $77.4 billion, a trailing P/E of 15.19, and a dividend yield near 1%. The 52-week range is $115.19 to $255.24. The consensus rating is Buy, with 7 of 11 analysts bullish, an average target of $223.36, a median of $210, a high of $310, and a low of $170. The framing is a low-cost senior gold producer trading well below its 52-week high where one of its more cautious covering firms has now turned constructive.
Risks: a stronger dollar or higher real yields can compress gold; permitting and grade-reconciliation issues can pressure unit costs; and jurisdictional exposure to Mexico and Finland introduces regulatory and tax risk.
Gilead Sciences (GILD) — HSBC turns positive after long stretch at Hold
Gilead is a large-cap biotech built on HIV, oncology, and virology franchises, with lenacapavir positioned as the growth engine into the back half of the decade. On July 6, HSBC analyst Morten Herholdt upgraded the stock from Hold to Buy and raised the target from $133 to $155, a $22 increase that follows earlier target hikes at HSBC and reflects growing confidence in the injectable-HIV pipeline. Cantor Fitzgerald's Carter Gould reiterated Overweight $155 the same day, Scotiabank's Louis Chen carries Sector Outperform $177, Needham's Joseph Stringer sits at Buy $170, and Wells Fargo's Mohit Bansal at Overweight $145.
Shares traded at $129.11 on July 6, down 1.64%, with a market cap of $160.3 billion, a trailing P/E of 15.43, and a dividend yield near 2%. The 52-week range is $107.75 to $157.29. The consensus rating is Strong Buy, with 9 of 10 analysts bullish, an average target of $159.60, a median of $161, a high of $177, and a low of $122. The framing is a defensive biotech where one of the last remaining Hold ratings has flipped and pushed near-unanimity to the bull side.
Risks: HIV franchise pricing and market-share pressure from GSK and ViiV; execution risk on lenacapavir launch dynamics; oncology pipeline setbacks; and continued policy risk on 340B and Part D reforms.
T-Mobile US (TMUS) — Bank of America restarts the bull case
T-Mobile is the wireless carrier whose 5G lead has driven multi-year postpaid share gains against AT&T and Verizon. On July 6, Bank of America analyst Michael Funk upgraded the stock from Neutral to Buy with a $220 target, calling out a favorable setup after the recent drawdown. UBS's John Hodulik holds Buy $255, JPMorgan's Sebastiano Petti carries Overweight $275, Wells Fargo's Eric Luebchow at Overweight $225, and Benchmark's Matthew Harrigan at Buy $295.
Shares traded at $181.64 on July 6, up 2.32%, with a market cap of $196.6 billion, a trailing P/E of 18.94, and a dividend yield near 2%. The 52-week range is $165.66 to $261.56. The consensus rating is Strong Buy, with 15 of 17 analysts bullish, an average target of $255, a median of $251, a high of $310, and a low of $220. The framing is a wireless leader roughly 30% off its 52-week high where a major sell-side firm has ended its extended stint on the sidelines.
Risks: competitive intensity from AT&T and Verizon device promos; slower postpaid net-add trajectory; capex requirements for standalone 5G and fiber build; and cable MVNO pressure on lower-tier ARPU.
U.S. Bancorp (USB) — Jefferies upgrades on NIM tailwind and capital-return path
U.S. Bancorp is the fifth-largest U.S. commercial bank, with a payments franchise anchored by Elavon and a retail deposit base concentrated across the Midwest and West. On July 6, Jefferies analyst David Chiaverini upgraded the stock from Hold to Buy and raised his target from $60 to $75, citing a constructive view on net interest margin, capital generation, and a 3% lift to his 2027 EPS estimate to $5.70. Wells Fargo's Mike Mayo held Overweight $66 and JPMorgan's Vivek Juneja maintained Underweight $65 on the same day, so the tape is not unanimous. Truist's John McDonald holds Buy $62 and DA Davidson's Peter Winter Buy $65.
Shares traded at $62.95 on July 6, up 1.97%, with a market cap of $98.1 billion, a trailing P/E of 13.20, and a dividend yield near 3%. The 52-week range is $43.46 to $63.05. The consensus rating is Buy, with 9 of 13 analysts bullish, an average target of $65.62, a median of $66, a high of $75, and a low of $59. The framing is a mid-cap money-center bank pushing on its 52-week high on renewed NIM optimism.
Risks: commercial real estate credit migration; deposit repricing pressure if the Fed stays on hold longer than expected; regulatory capital rules for Category II banks; and slower-than-expected Elavon merchant volume growth.
Okta (OKTA) — Scotiabank finally turns constructive on identity
Okta is the enterprise identity and access management platform, with expanding footprint in customer identity and privileged access. On July 6, Scotiabank analyst Patrick Colville upgraded the stock from Sector Perform to Sector Outperform and raised his target from $135 to $165, ending a long stretch of neutral coverage from one of the more cautious shops on the name. KeyBanc's Jackson Ader holds Overweight $130, RBC's Matthew Hedberg Outperform $122, JPMorgan's Brian Essex Overweight $114, and Cantor Fitzgerald's Jonathan Ruykhaver Overweight $110.
Shares traded at $146.58 on July 6, up 3.65%, with a market cap of $24.3 billion and a trailing P/E of 41.41. The 52-week range is $62.66 to $148.83. The consensus rating is Strong Buy, with 17 of 22 analysts bullish, an average target of $123.55, a median of $120, a high of $165, and a low of $100. The framing is a cybersecurity name pressing its 52-week high where a formerly cautious firm now sees the highest target on the Street.
Risks: the stock trades above the consensus target, suggesting near-term multiple risk; competition from Microsoft Entra ID on identity bundling; slower net-new customer adds; and continued reputational overhang from the 2023 support-system breach.
Found this helpful? Share it with others.